23 results about "Ginkgolide" patented technology

The invention relates to the technical field of medicines, in particular to application of ginkgo terpene lactones in preparation of medicines for preventing and / or treating Parkinson's disease. The bilobalide and the composition or extract thereof can improve the motion coordination of Parkinson's disease model mice, have a treatment effect on Parkinson's disease, and can be used for preparing drugs for treating Parkinson's disease.

The invention provides application of ginkgo terpene lactones, bilobalide or stereoisomers thereof in preparation of drugs for preventing or treating hyperlipidemia and hyperlipidemia complications.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The invention provides a pharmaceutical composition, a preparation as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises bilobalide B and dextroborneol, the weight ratio of the bilobalide B to the dextroborneol is (0.02 to 50): 1. In the pharmaceutical composition disclosed by the invention, bilobalide B and dextroborneol can play a synergistic effect, and the pharmaceutical composition has an excellent effect, small side effects and an excellent clinical application prospect when being used for treating cerebral arterial thrombosis; the traditional Chinese medicine composition is novel in formula, simple in component, clear in action mechanism, remarkable in curative effect, not prone to tolerance generation and capable of achieving large-scale industrial production.

This invention provides a composition of Ginkgo biloba extract and its preparation method. The composition consists of Ginkgo biloba extract (calculated as total flavonol glycosides) and dipyridamole in a dosage ratio of 10:4. The preparation method can significantly improve product yield, reduce production costs, and significantly increase the content of the main components of the produced Ginkgo biloba extract, namely total flavonol glycosides and terpene lactones. It can also reduce the content of poorly water-soluble ginkgolides and harmful impurities such as ginkgolic acid, control its microbial level, and improve the stability and safety of the Ginkgo biloba extract preparation product of this invention.

The invention relates to the technical field of biology, and particularly discloses application of bilobalide B in plateau environment cognitive dysfunction protection. The application comprises the steps that a pharmaceutical composition containing bilobalide B is mixed with a low-concentration oxygen adaptation regulating agent to be used for regulating the pharmaceutical composition, and an intermediate product with the nerve protection enhancing effect is obtained; carrying out nano-carrier packaging and functionalization treatment on the intermediate product with the effect of enhancing neuroprotection, so as to realize brain-targeted controlled release of the drug to obtain a composite controlled release drug; the compound controlled-release medicine is administrated by adopting an administration dosage optimization method based on reinforcement learning, so that long-term prevention and improvement of cognitive impairment in a plateau environment are realized, and a final cognitive function protection effect is obtained; the whole formula is regulated and controlled by a nano controlled release technology, and all the components can be continuously released and uniformly distributed, so that the optimal balance between the drug effect and the safety is realized, and the problem of cognitive impairment caused by high altitude hypoxia is comprehensively improved.

The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and / or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w / w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w / w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w / w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w / w of the composition. Such compositions are useful for improving memory and / or focus.

The invention provides application of bilobalide B in inhibiting cerebral ischemia reperfusion injury caused by ferroptosis, and relates to the field of cerebral ischemia reperfusion injury. According to the application, ginkgolide B inhibits ferroptosis by regulating an Nrf2 / H0-1 pathway so as to improve cerebral ischemia reperfusion injury, regulation of Nrf2 / H0-1 promotes nuclear translocation of Nrf2 and up-regulates expression of a downstream antioxidant gene HO-1 so as to relieve spinal cord injury by inhibiting ferroptosis, and up-regulation of the expression of the downstream antioxidant gene HO-1 is that when cells are stimulated by hypoxia, the expression of the downstream antioxidant gene HO-1 is inhibited so as to inhibit the ischemia reperfusion injury. And the Nrf2 is dissociated from the Keap1 and is translocated to a cell nucleus. The action mechanism of the ginkgolide B for inhibiting the ferroptosis process and improving the CIRI by regulating and controlling an Nrf2 / HO-1 signal channel is explored, and a research strategy of combining bioinformatics prediction and experimental verification is adopted, so that a foundation is laid for deeply analyzing the neuroprotective action mechanism of the ginkgolide B; and a new research thought and a potential target spot are provided for developing a novel ginkgo leaf-related active ingredient medicine.

The invention discloses application of bilobalide in inhibiting migration and invasion of ovarian cancer cells, and relates to the technical field of biological medicines. Application of bilobalide in preparation of drugs for inhibiting migration and invasion of ovarian cancer cells; the concentration of the bilobalide is 5 [mu] M to 40 [mu] M. In the application of the bilobalide, the bilobalide shows an obvious growth inhibition effect on ovarian cancer cells and has no obvious influence on the survival rate of normal ovarian cells; in a concentration range of 5-40 [mu] M, bilobalide shows dose dependence on activity inhibition of SKOV3 and ID-8 cells, but has small influence on IOSE80 cells, and shows a good safety window; compared with a traditional chemotherapeutic drug, the bilobalide as a natural compound has better biocompatibility, and is expected to be capable of remarkably relieving common toxic and side effects such as myelosuppression and liver and kidney function impairment in clinical application.

The application provides a sugar alcohol solvent and its application in preparation of a product containing ginkgo leaf extract, and belongs to the technical field of food and health care products. The sugar alcohol solvent comprises xylitol, and the mass percentage of xylitol in the sugar alcohol solvent is 30-50%. The sugar alcohol solvent is safe and non-toxic, has simple preparation process and low cost, can be used as a solubilizing solvent for the ginkgo leaf extract, can improve the solubility of the ginkgo leaf extract without affecting the stability and biological activity of ginkgolides and ginkgo flavones in the ginkgo leaf extract, can be used as an intermediate purification solvent for preparation of ginkgolide monomers, is safe and non-toxic, and can be used as a new solvent for the ginkgo leaf extract to prepare a liquid oral ginkgo leaf extract, so that liquid health care is realized, and safe drug delivery is realized for diagnosis and treatment of cardiovascular and cerebrovascular diseases of special groups (such as diabetic patients).

The application provides ginkgolide bulk drug. The application further provides a preparation method of the ginkgolide bulk drug and application thereof. The ginkgolide and the preparation method thereof can obtain high-quality ginkgolide bulk drug through the preferred preparation steps and conditions. Compared with the ginkgolide prepared by a conventional method, the ginkgolide has stable quality, low unqualified rate and good consistency of different batches of bulk drugs.

The invention discloses application of a DNA methylation inhibitor in regulation and control of synthesis of ginkgo terpene lactones in the technical field of plant cultivation, and the epigenetic regulation and control effect of 5-azacytidine on leaf growth and terpene lactones synthesis is researched by taking ginkgo as a material. 5-AzaC with different concentrations is set for treatment, and the dynamic change of leaf growth traits and terpene lactone accumulation is systematically analyzed. Researches show that treatment of 5-AzaC shows a significant dose effect: low concentration (50 [mu] mol / L) promotes increase of fresh weight and increase of terpene lactone content, and high concentration (greater than or equal to 150 [mu] mol / L) inhibits growth but significantly increases accumulation of bilobalide and ginkgolide C. Correlation analysis shows that biomass and terpene lactone content are in significant negative correlation, a growth and defense balance phenomenon is proved, the invention reveals that 5-AzaC affects synthesis and accumulation of different terpene lactones by regulating DNA methylation level difference, and a theoretical basis and a technical path are provided for accurate regulation of ginkgo medicinal components.

The present application provides a kind of pharmaceutical composition for vulvar sclerosing lichen and its preparation method, the pharmaceutical composition includes active ingredient and pharmaceutically acceptable vulva local administration adjuvant, active ingredient is made of 0.005-0.02 parts of mometasone furoate, 0.05-0.3 parts of calcineurin inhibitor, 0.5-2 parts of paeoniflorin, 0.8-3 parts of asiaticoside, 0.3-1.5 parts of recombinant collagen, 0.2-1 part of ginkgolide B.The present application is aimed at the core pathogenesis of disease, constructs multi-target whole course of disease synergistic therapy system, can realize anti-inflammatory regulation, anti-fibrosis, basement membrane repair, microcirculation improvement simultaneously, low-dose strong effect, greatly reduce side effect and recurrence rate;Liposome targeted delivery technology is used, the stability of active ingredient is guaranteed, process controllable adaptation industrialization production, and clinical application prospect is wide.

The present invention relates to a synergistic composition for controlling headache disorders. The composition comprises Palmitoylethanolamide, Magnesium, and Ginkgolide B, along with pharmaceutically acceptable excipients. The invention addresses primary headache disorders, including migraine and tension-type headaches, which represent the majority of headache disorders. Palmitoylethanolamide exhibits analgesic and anti-inflammatory properties, down¬ regulating pro-inflammatory and nociceptive pathways. Magnesium contributes to the reduction of headache symptoms, while Ginkgolide B, derived from Ginkgo biloba, enhances the therapeutic effect. Animal studies have demonstrated the synergistic efficacy of this combination in reducing the frequency, duration, and severity of headache symptoms, both independently and when used with standard treatments.

The invention discloses a gene GbSAUR48 for promoting synthesis and biomass of bilobalide as well as a carrier, a protein and application of the gene GbSAUR48. The nucleotide sequence of the gene GbSAUR48 is shown as SEQ ID NO. 1. According to the invention, the GbSAUR48 gene specifically and highly expressed in the ginkgo biloba root reveals dual functions of the GbSAUR48 gene in promoting lateral root generation, improving overground and underground biomass and promoting bilobalide synthesis for the first time. The number of fibrous roots / lateral roots and the overall overground / underground biomass of the plant over-expressed with GbSAUR48 are remarkably increased, and meanwhile the content of active terpene lactones (GA and GB) is synchronously increased. The invention not only shows that the GbSAUR48 is a key gene for regulating and controlling the quality (medicinal quality) and yield (biomass) of the gingko, but also provides a new theoretical basis and a practical path for realizing double improvement of the medicinal value and the yield of the gingko through a molecular breeding means.

The invention relates to the technical field of medicines, in particular to application of ginkgo terpene lactone in preparation of medicines for prevention, treatment and / or adjuvant treatment of prostatic cancer. The ginkgo terpene lactone and a composition or extract thereof can inhibit cell proliferation of prostatic cancer cell lines, have a quality effect on prostatic cancer, and can be used for preparing medicines for preventing, treating and / or adjunctively treating prostatic cancer. The compound can be used for preparing medicines for treating prostatic cancer.

The invention relates to the technical field of plant genetic engineering, in particular to a ginkgo terpene synthase gene GbTPS13 and application of the ginkgo terpene synthase gene GbTPS13 in heterologous synthesis of a bilobalide precursor in tobacco. The nucleotide sequence of the ginkgo terpene synthase gene GbTPS13 is as shown in SEQ ID NO. 1, and the coded amino acid sequence is as shown in SEQ ID NO. 2; ginkgo biloba diterpene synthase GbTPS13 is identified in tobacco tissues, L-pimaric diene can be catalytically generated through overexpression of GbTPS13 in tobacco, the diterpene compound is a common precursor of bilobalide, and the method is used for constructing a tobacco chassis system capable of being used for synthesizing bilobalide. And a potential starting platform and basic framework are provided for complete and large-scale biosynthesis of bilobalide.

The present invention relates to a method for extracting and purifying ginkgolide B. The method comprises: (1) crushing ginkgo leaves, adding a mixed acid solution for soaking and extraction; (2) concentrating ginkgo leaf extract 1, boiling, adding talcum powder, filtering, refrigerating, and filtering; (3) adding ethyl acetate to extract 2, separating the layers, adding water, separating the layers, filtering, and spin-drying; (4) dissolving the crude extract in ethanol, eluting through a superacidic alumina chromatography column; (5) concentrating the eluate, refrigerating, filtering, and drying; (6) adding the crude ginkgolide B to a mixed solution of n-heptane and ethanol for crystallization. This method not only solves the problems of low extraction rate in steam distillation and large amount of solvent loss in organic solvent extraction, but also improves the yield of ginkgolide B while ensuring the purity of ginkgolide B. It has the advantages of simple preparation process, easy operation, low organic solvent consumption, low cost, high yield and purity, and is suitable for industrial production.

The application relates to application of ginkgo biloba lactone A in preparation of drugs against white spot syndrome, aiming at the problem that effective treatment drugs are still lacking for the destructive damage of white spot syndrome virus (WSSV) to aquatic crustaceans, and providing a new application of ginkgo biloba lactone A; through in-vitro experiment of Hpt cells of astacus leptodactylus and in-vivo feeding experiment of astacus leptodactylus, it is verified that the ginkgo biloba lactone A can significantly inhibit WSSV replication at a concentration of 100 muM; the astacus leptodactylus is fed with 40 mg / kg feed for 10 days, the survival rate after being infected with WSSV is increased by about 53.3%, meanwhile, the expression of immune-related genes is up-regulated, the apoptosis rate of blood cells is reduced, and the virus replication is significantly inhibited; a safe and efficient new drug for the prevention and control of WSSV in aquatic breeding is provided, and has important industrial application value.

The application discloses a kind of functionalization exosome-traditional Chinese medicine small molecule composite preparation T-pEXOs@GB and its preparation method and application.The composite preparation encapsulates ginkgolide B (GB) in the exosome of healthy plasma, and is functionally modified neuron target peptide RVG (DSPE-PEG-RVG) on its surface, so that it has brain targeting and oxygen supply functions.The preparation method provided by the application can efficiently and controllably prepare the composite preparation with uniform particle size and good stability.The T-pEXOs@GB composite preparation of the application can be targeted to deliver to brain ischemia and hypoxia injury area, significantly reduce oxidative stress and inflammatory response, reduce cerebral infarction volume, improve neurological deficit score, and improve the survival rate of animal model, and can be used to prepare drugs for preventing and treating acute high altitude cerebral hypoxia, ischemic stroke, neonatal hypoxic-ischemic encephalopathy and other cerebral ischemia and hypoxia injury, and has good market prospect.

This invention discloses a platelet-loaded bio-nanomedicine containing ginkgolide and butylphthalide, its preparation method, and its application, relating to the field of pharmaceutical formulation technology. The bio-nanomedicine comprises an active ingredient, a core drug carrier, a biological shell, and a target-seeking peptide. The active ingredient includes at least ginkgolide B and butylphthalide. The core drug carrier includes a lipid carrier, and the target-seeking peptide is a CITP peptide. The mass ratio of the active ingredient to the core drug carrier is 1:5 to 1:10. The amino acid sequence of the CITP peptide is PHSSHIGTTEIGKL. The biological shell includes at least one of platelet membrane and exosome membrane. The bio-nanomedicine of this invention exhibits good targeting and therapeutic efficacy, providing a new approach for the treatment of thrombotic diseases.

The application discloses a kind of pharmaceutical composition for treating pulmonary fibrosis and application thereof, belong to biological medicine technical field.The ginkgolide K (GinK) raw material source of the present application is easy, preparation cost is low, with lower toxicity, as natural industrialization small molecule.Small molecule STING inhibitor C176 has the ability to inhibit STING signal and have positive effect on fibrosis endpoint, can clearly target inhibition STING signal.Ginkgolide K (GinK) and small molecule STING inhibitor C176 are combined to use, can improve histological lesions and down-regulate the expression of several fibrosis-related proteins, have obvious synergistic effect on histological improvement, fibrosis-related protein expression inhibition and other endpoints, so as to achieve the synergistic effect that single drug is difficult to achieve, and reduce the potential toxicity and cost problem brought by single drug high dose.

The invention discloses graphene oxide loaded bilobalide B and a preparation method thereof. The graphene oxide loaded bilobalide B comprises graphene oxide, a polymer, bilobalide B and ferritin, the graphene oxide, the polymer and the ferritin are subjected to covalent bond grafting to complete functional modification, so that the stability and the biocompatibility are improved; the graphene oxide is modified by the polymer NPs to obtain the flaky graphene oxide / polymer NPs, so that the dispersity and biocompatibility of the graphene oxide are greatly improved; modifying the graphene oxide through protein to obtain a dual-modified targeted graphene oxide drug delivery system; the bilobalide B is loaded on the dual-modified targeted graphene oxide, so that the problem of poor solubility of the bilobalide B is greatly improved, and meanwhile, the drug loading capacity of the bilobalide B is also improved; the preparation method and the production process are relatively simple, the yield is high, and a final product solvent is water and is non-toxic.